Cointime

ProteoMediX

company

About

ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer.

  • 1 - 10

Highlights

Total Funding Amount
Fr11M
Funding Rounds
3
Investors
3

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
Fr5.20M
Industries
Biotechnology,Health Care,Medical
Founded date
Mar 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer and the personalized treatment thereof.The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
Fr11M
ProteoMediX has raised a total of Fr11M in funding over 2 rounds. Their latest funding was raised on Aug 27, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 27, 2018 Series Unknown Fr5.20M 2 Altos Venture — Detail
Apr 9, 2014 Series B Fr3.20M 1 Altos Venture — Detail
Jan 12, 2012 Series A Fr2.60M 2 Altos Venture — Detail

Investors

Number of Lead Investors
Number of Investors
3
3
ProteoMediX is funded by 3 investors. Altos Venture and several private are the most recent investors.
Investor Name Lead Investor Funding Round
Altos Venture Yes Series Unknown
several private — Series Unknown
BioValley Business Angels Club (BioBAC) — Series A
Cointime
Содержание
компания